Idasanutlin

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameIdasanutlin
Drug Alias Name伊达努林IdasanutlinaIdasanutline依达奴林Idasanutlinum +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsSolid tumoursThrombocythemia, EssentialCentral Nervous System Neoplasms +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaPanama +[30] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche AgF. Hoffmann-La Roche LtdRoche (China) Holding Ltd
Inactive CompaniesRoche Pharma AgGenentech IncJohn Mascaren As +[4] 
Active IndicationsSolid tumoursPolycythemia VeraLeukemia, Myeloid, Acute
Inactive IndicationsThrombocythemia, EssentialCentral Nervous System NeoplasmsBreast Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A